CW February 2006
Volume 15Issue Number 2 February 2006 ISSN 10593802 FDA Approves a New Drug Combination Regimen for NHL PatientsThe Food and Drug Administration (FDA) has approved Rituximab, an antibody against CD20-positive B-cells for use in combination with standard anthracycline-based chemotherapeutic agents in the treatment of diffuse large cell lymphoma expressing CD20.
Go to Previous Page Go to Next Page Source & Additional Reading Source: News Release Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
